Dennis Brooks
Impact in
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
- Drug Solubulity and Delivery Systems
- Health top 10%
- Vaccine Coverage and Hesitancy
Papers in
-
- Influenza Virus Research Studies 3
- Respiratory viral infections research 3
-
- Viral gastroenteritis research and epidemiology 3
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Jeffrey L. Cleland (3 shared papers)Paul M. Darden (4 shared papers)Richard C. Wasserman (3 shared papers)Chung C. Hsu (3 shared papers)Alison B. Bocian (3 shared papers)Venkat R. Mukku (2 shared papers)Herman Chu (2 shared papers)Andrew J. S. Jones (2 shared papers)
- Journals
- PEDIATRICS (3 papers)Pharmaceutical Research (2 papers)Biomaterials (1 paper)Journal of Pharmaceutical Sciences (1 paper)Vaccine (1 paper)
- Partner nations
- United StatesUnited KingdomSweden
In The Last Decade
Dennis Brooks
14 papers receiving 546 citations
Dennis Brooks's Hit Papers
Peers
Comparison fields: 5 of 93
- Pharmaceutical Science 129
- Health 90
- Infectious Diseases 161
- Molecular Medicine 28
- Biomaterials 72
Countries citing papers authored by Dennis Brooks
This map shows the geographic impact of Dennis Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Brooks more than expected).
Fields of papers citing papers by Dennis Brooks
This network shows the impact of papers produced by Dennis Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Brooks. The network helps show where Dennis Brooks may publish in the future.
Co-authors
The 25 scholars most cited alongside Dennis Brooks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2022 | 127 |
| 2 | 1997 | 87 | |
| 3 | 1995 | 72 | |
| 4 | 2002 | 67 | |
| 5 | 2002 | 54 | |
| 6 | 1997 | 54 | |
| 7 | 2010 | 35 | |
| 8 | 2002 | 27 | |
| 9 | 1997 | 12 | |
| 10 | 2001 | 12 | |
| 11 | 2023 | 11 | |
| 12 | 2021 | 2 | |
| 13 | 2007 | 2 | |
| 14 | 2024 | 1 |
About Dennis Brooks
Dennis Brooks is a scholar working on Epidemiology, Infectious Diseases, Health, Endocrinology, Diabetes and Metabolism and Surgery, having authored 14 papers that have together received 563 indexed citations. Recurring topics across this work include Vaccine Coverage and Hesitancy (4 papers), Growth Hormone and Insulin-like Growth Factors (3 papers), Influenza Virus Research Studies (3 papers), Respiratory viral infections research (3 papers), Viral gastroenteritis research and epidemiology (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Salivary Gland Disorders and Functions (2 papers) and Congenital Diaphragmatic Hernia Studies (1 paper). The work is most often cited by research in Pharmaceutical Science (129 citations), Health (90 citations), Infectious Diseases (161 citations), Molecular Medicine (28 citations) and Biomaterials (72 citations). Dennis Brooks has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Jeffrey L. Cleland, Paul M. Darden, Richard C. Wasserman, Chung C. Hsu, Alison B. Bocian, Venkat R. Mukku, Herman Chu, Andrew J. S. Jones, Eileen Duenas and James A. Taylor. Their work appears in journals such as PEDIATRICS, Pharmaceutical Research, Biomaterials, Journal of Pharmaceutical Sciences and Vaccine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.